IBMS/ECTS 2001 - PROGRAM and ABSTRACTS
HOT TOPICS
Chairs: Gideon A. Rodan (West Point, PA/USA),
Stuart H. Ralston (Aberdeen/UK)
Sunday, June 10, 2001
09:00 - 10:00 Auditorium
- IN16
- Mediating Transcriptional Activation by the Vitamin D3 Receptor
- Leonard P. Freedman (New York, NY/USA)
- IN17
- Regulation and Function of Vertebrate Hox Genes during Limb Development and Evolution
- Denis Duboule (Geneva, Switzerland)
HOT TOPICS
Chairs: Gideon A. Rodan (West Point, PA/USA),
Stuart H. Ralston (Aberdeen/UK)
Sunday, June 10, 2001
10:30 - 12:30 Auditorium
The abstract text of oral presentations (prefix OR) can be found in the Abstracts section.
- 10:30 OR71
- THE ORPHAN RECEPTOR, ESTROGEN RELATED RECEPTOR ERRA, IS HIGHLY EXPRESSED IN OSTEOBLASTS AND IS REQUIRED FOR BONE FORMATION
- E. Bonnelye*, L. Meerdad, J. E. Aubin
- University of Toronto, Ontario, Canada
- 10:42 OR72
- LONG-TERM POTENTIATION IN BONE: A CELLULAR BASIS OF MEMORY IN OSTEOBLASTS?
- G. J. Spencer*, T. S. Grewal, P. G. Genever, T. M. Skerry
- Univesity of York, York, UK
- 10:54 OR73
- THE DIRECT ACTIONS OF LEPTIN ON BONE CELLS INCREASE BONE STRENGTH IN VIVO - AN EXPLANATION OF LOW FRACTURE RATES IN OBESITY
- J. Cornish*, K. E. Callon, U. Bava, Q. X. Lin, D. Naot, B. L. Hill, N. D. Broom, I. R. Reid
- University of Auckland, Auckland, New Zealand
- 11:06 OR74
- LEPTIN REGULATES BONE MASS IN RATS
- A. F. Schilling*, T. Holzmann, J. M. Rueger, G. Karsenty, M. Amling
- Hamburg University, Germany; Baylor College, Houston, USA
- 11:18 OR75
- LIGAND-RECEPTOR INTERACTIONS REGULATING CELLULAR TRAFFICKING AND SIGNALING OF THE HUMAN PARATHYROID HORMONE/ PARATHYROID HORMONE-RELATED PROTEIN RECEPTOR
- S. L. Ferrari*, L. Monticelli, D. Mierke, A. Bisello
- Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA; University Hospital, Geneva, Switzerland; Brown University, RI, USA; University of Pittsburgh Medical Center, PA, USA
- 11:30 OR76
- THE CARBOXY-TERMINAL, "OSTEOSTATIN", REGION OF PTH-RELATED PROTEIN IS ESSENTIAL FOR INDUCTION OF CELLULAR PROLIFERATION FOLLOWING NUCLEAR ENTRY.
- N. M. Fiaschi-Taesch*, F. deMiguel, J-C. Lopez-Talavera, K. K. Takane, T. Massfelder, J-J. Helwig, A. F. Stewart
- Division of Endocrinology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Université Louis Pasteur, Strasbourg, France
- 11:42 OR77
- MUTATIONS IN SOST, A NOVEL SECRETED PROTEIN, CAUSE INCREASED BONE FORMATION IN SCLEROSTEOSIS
- W. Balemans*, M. Ebeling, N. Patel, E. Van Hul, P. Olson, M. Dioszegi, C. Lacza, W. Wuyts, J. Van Den Ende, P. Willems, A. F. Paes-Alves, S. Hill, M. Bueno, F. J. Ramos, P. Tacconi, F. G. Dikkers, K. Lindpaintner, B. Vickery, D. Foernzler, W. Van Hul1
- Dept. Medical Genetics, Antwerp, Belgium; F. Hoffmann-La Roche Ltd, Basel, Switzeland; Roche Bioscience, Palo Alto, USA; Dept. Clinical Genetics, Rotterdam, The Netherlands; Departamento de Ginecologica, Salvador, Brazil; National Institutes of Health, Bethesda, USA; Universidad de Zaragoza, Spain; Instituto di Neurologia, Cagliari, Italy; University Hospital Groningen, Groningen, The Netherlands; Roche Genetics, Basle, Switzerland
- 11:54 OR78
- FGF23 AS A CAUSATIVE FACTOR OF HYPOPHOSPHATEMIC DISEASES
- T. Shimada, S. Mizutani, T. Muto, T. Yoneya, R. Hino, Y. Takeuchi, T. Fujita, S. Fukumoto, T. Yamashita*
- KIRIN Pharmaceutical Research Lab., Takasaki, Japan; University of Tokyo School of Medicine, Tokyo, Japan; University of Tokyo Branch Hospital, Tokyo, Japan
- 12:06 OR79
- STATIN USE AND FRACTURE: A META-ANALYSIS OF 8 OBSERVATIONAL STUDIES
- D. C. Bauer*, D. M. Black, M. van der Klift
- University of California, San Francisco, USA; Erasmus University, Rotterdam, Netherlands
- 12:18 OR80
- A SINGLE ANNUAL INJECTION OF THE BISPHOSPHONATE, ZOLEDRONIC ACID, STABLY REDUCES BONE TURNOVER AND INCREASES BONE DENSITY IN POSTMENOPAUSAL OSTEOPOROSIS
- I. R. Reid*, J. Brown, P. Burckhardt, Z. Horowitz, P. Richardson, U. Trechsel, for the Zoledronic Acid Study Group
- Medicine, University of Auckland, New Zealand; Universitaire de Quebec-Le Centre Hospitalier, Sainte-Foy, PQ, Canada; CHUV University Hospital, Lausanne, Switzerland.; Novartis
